Valneva announces the availability of documentation for its
Holy-Herblain (France), June 2, 2021 – Valneva SE (“Valneva” or “the Company”), a specialist vaccines company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announces that its Combined General Meeting will be held in camera on June 23, 2021 at 2:00 p.m. CEST, at its head office located at 6 rue Alain Bombard, 44800 Saint-Herblain (France).
Due to the current COVID-19 pandemic and in accordance with French ordinance n ° 2020-321 of March 25, 2020 and French decree n ° 2020-418 of April 10, 2020 in their versions in force on the date hereof, and as resulting in particular from French decree n ° 2021-255 of March 9, 2021 extending until July 31, 2021 the measures to adapt the regulations for meetings and management bodies of legal persons and without legal personality under private law due In the event of a COVID-19 pandemic, the Company has decided to hold its Combined General Meeting without the physical presence or participation by telephone or videoconference of shareholders and other persons authorized to attend.
Valneva will provide a live webcast of the conference to allow all those normally authorized to attend the General Assembly to follow it remotely. This webcast will be accessible on the home page or in the “Investors” / “Videos and Webcasts” section of the Company’s website www.valneva.com, and a replay will be available after the event.
The Preliminary Notice of Meeting, including the Agenda and the Draft Resolutions, has been published in French Bulletin of Advertisement Legal Obligatory (BALO) of May 19, 2021. The specific conditions for participating in this in camera Combined General Meeting, in their latest version updated on the date hereof, are available in the section “Investors” / “General Meetings” / “ Combined General Meeting 2021 ”on the Company’s website www.valneva.com.
Valneva SE shareholders can only exercise their voting rights before the Meeting and remotely, including via the Internet, either by voting by post or by giving proxy. To this end, the shareholders of the Company may:
- use the VOTACCESS online platform (recommended method), or
- use the Single Vote by correspondence or the Form of Proxy, published in the “Investors” / “General Meetings” / “Combined General Meeting 2021” section of the Company’s website www.valneva.com.
No admission card will be issued.
Please note that during the General Assembly it will not be possible to ask questions, submit draft amendments or submit new resolutions.
Shareholders can obtain the documents of the Combined General Meeting referred to in Articles R. 225-81 and R. 225-83 of the French Commercial Code upon request addressed to the Company. Valneva recommends that shareholders send their requests by email to the following address: [email protected]
In addition, shareholders may also exercise their right of communication and receive a copy by email of the documents referred to in Articles L. 225-115, L. 225-116 and L. 225-117 of the Commercial Code (including in particular the list shareholders) and which are not accessible on the Company’s website, upon simple request made by e-mail or by mail, under the conditions and within the time limits respectively provided for in Articles R. 225-89, R. 225-90 and L. 225-117 of the French Commercial Code. Valneva recommends that its shareholders send these requests to the following address: [email protected]
Finally, the Company recommends that its shareholders regularly consult the section relating to the General Meeting in the “Investors” / “General Meetings” / “Mixed General Meeting 2021” section of the Company’s website www.valneva.com.
|General Assembly Service contact details
General Assembly Service
6 rue Alain Bombard, 44800 Saint-Herblain (France)
Valneva Investor and Media Contact
Director of Investor Relations & Corporate Communication
M +33 (0) 6 4516 7099
About Valneva SE
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines against infectious diseases for which a significant medical need is not met. We take a highly specialized and targeted approach to vaccine development, starting with the identification of fatal and debilitating infectious diseases for which there is no prophylactic vaccine solution and for which therapeutic treatment options are limited. We then apply our in-depth understanding of vaccine science, including our expertise in several vaccine modalities, as well as our established vaccine development capabilities, to develop prophylactic vaccines to combat these diseases. We have leveraged our expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a wide range of vaccine candidates in and across the clinic, including candidates for Lyme disease, the virus. chikungunya and COVID-19.
Valneva forward-looking statements
This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing, results and completion of research, development and clinical trials for product candidates and estimates of future performance. In addition, even if the actual results or developments of Valneva are consistent with the forward-looking statements contained in this press release, these results or developments of Valneva may not be maintained in the future. In some cases, you can identify forward-looking statements by words such as “could”, “should”, “could”, “expects”, “anticipates”, “believes”, “intends”, “Estimates”, “aims,” ”targets”, or similar words. These forward-looking statements are based largely on Valneva’s current expectations as of the date of this press release and are subject to a number of risks and uncertainties. known and unknown and other factors that may cause actual results, performance or achievements to differ from future results, performance or achievements expressed or implied by these forward-looking statements. In particular, Valneva’s expectations could be affected, among others, uncertainties related to vaccine development and manufacturing, unexpected clinical trial results, unexpected regulatory actions or delays, general competition, fluctuations in quotes es, the impact of global markets and the credit crunch in Europe and the ability to obtain or maintain patent or other proprietary intellectual property protection. The success of preclinical studies or previous clinical trials may not be indicative of the results of future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this presentation will actually be realized. Valneva provides the information contained in these documents from this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.